Medtronic is recalling certain MiniMed 600 Series insulin pumps due to a missing or broken retainer ring that can potentially lead to the under or over delivery of insulin.
A novel dual-hormone artificial pancreas system that delivers both rapid insulin and pramlintide was found to improve glucose control.
Real-world use of continuous glucose monitoring systems improves glycemic control and reduces the frequency of rare and dangerous events in pediatric type 1 diabetes.
Automated insulin delivery by a mobile closed-loop control system represents a feasible option for glycemic control in type 1 diabetes, with some improvements still needed in device connectivity.
Researchers explored the effects of a telemedicine visit on care in patients with T1D.
Intermittently scanned continuous glucose monitoring results in higher treatment satisfaction among adults with type 1 diabetes.
The American Diabetes Association (ADA) has published an update to their Standards of Medical Care in Diabetes for 2020.
A closed-loop insulin delivery system, also referred to as an artificial pancreas, was found to be more effective than sensor-augmented insulin pump therapy in patients with type 1 diabetes.
The FDA has expanded the indication for Fiasp (insulin aspart injection; Novo Nordisk) 100 Units/mL to include use in insulin infusion pumps to improve glycemic control in adults with type 1 or type 2 diabetes.
There were no clear benefits of using faster insulin aspart in closed-loop insulin therapy and the closed-loop algorithm was better adjusted to the use of standard insulin aspart.
Medical devices that can connect to the internet might be at risk for hacking, the U.S. Food and Drug Administration warned Tuesday.